These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1198421)

  • 1. Proceedings: Clinical thrombosis. A subunit study of the fibrin.
    Strachan CJ; Gaffney PJ
    Thromb Diath Haemorrh; 1975 Nov; 34(2):551-2. PubMed ID: 1198421
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients.
    Jespersen J
    Dan Med Bull; 1988 Feb; 35(1):1-33. PubMed ID: 3277796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 4. [Natural inhibitors of fibrinolysis and thrombohemorrhagic phenomena].
    Moriau M
    Pathol Eur; 1969; 4():Suppl 1:9-286. PubMed ID: 4244510
    [No Abstract]   [Full Text] [Related]  

  • 5. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients.
    Andrew M
    Thromb Haemost; 1995 Jul; 74(1):415-25. PubMed ID: 8578498
    [No Abstract]   [Full Text] [Related]  

  • 6. [Role of fibrin formation processes in cerebrovascular diseases].
    Levati A; D'Angelo VA; Farina ML; Donati MB
    Recenti Prog Med; 1981 Dec; 71(6):601-11. PubMed ID: 7339747
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrin-fibrin and alpha 2-antiplasmin-fibrin cross-linking by platelet factor XIII increases the resistance of platelet clots to fibrinolysis.
    Reed GL; Matsueda GR; Haber E
    Trans Assoc Am Physicians; 1991; 104():21-8. PubMed ID: 1845147
    [No Abstract]   [Full Text] [Related]  

  • 8. Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms.
    Pandi L; Kollman JM; Lopez-Lira F; Burrows JM; Riley M; Doolittle RF
    Biochemistry; 2009 Aug; 48(30):7201-8. PubMed ID: 19588915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: Lysis of crosslinked and non-crosslinked purified fibrin.
    Haverkate F
    Thromb Diath Haemorrh; 1975 Nov; 34(2):584-5. PubMed ID: 1198489
    [No Abstract]   [Full Text] [Related]  

  • 10. The haemostatic balance in groups of thrombosis-prone patients. With particular reference to fibrinolysis in patients with myocardial infarction.
    Gram J
    Dan Med Bull; 1990 Jun; 37(3):210-34. PubMed ID: 2192835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: Fibrinogen-fibrin degradation products in thromboembolism and other diseases.
    Jones DR; Ruckley CV; Crqaigen A; Allan NC
    Br J Surg; 1974 Apr; 61(4):331-2. PubMed ID: 4832678
    [No Abstract]   [Full Text] [Related]  

  • 12. The assembly and structure of the fibrin clot.
    Mosesson MW
    Nouv Rev Fr Hematol (1978); 1992; 34(1):11-6. PubMed ID: 1523091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.
    Schoots IG; Levi M; van Vliet AK; Declerck PJ; Maas AM; van Gulik TM
    Thromb Haemost; 2004 Mar; 91(3):497-505. PubMed ID: 14983225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin degradation products. A review of structures found in vitro and in vivo.
    Gaffney PJ
    Ann N Y Acad Sci; 2001; 936():594-610. PubMed ID: 11460518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemostatic factors and coronary heart disease.
    Pilgeram LO
    Biomed Pharmacother; 1982; 36(4):187-9. PubMed ID: 7165789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Examination of blood coagulation and fibrinolysis in patients with increased tendency to thrombosis].
    Tengborn L; Wallmark A; Olsson K; Heijkenskjöld AM
    Lakartidningen; 1988 May; 85(18):1608-11. PubMed ID: 3361997
    [No Abstract]   [Full Text] [Related]  

  • 17. [Atherogenic modifications of low density lipoproteins during fibrin formation and fibrinolysis].
    Chulkova TM
    Vopr Med Khim; 1989; 35(2):72-5. PubMed ID: 2741416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of hypercoagulable states with protamine sulphate tests.
    Lipinski B
    Acta Univ Carol Med Monogr; 1972; 52():185-8. PubMed ID: 4273929
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.
    He S; Zhu K; Skeppholm M; Vedin J; Svensson J; Egberg N; Blombäck M; Wallen H
    Thromb Haemost; 2007 Oct; 98(4):871-82. PubMed ID: 17938814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.